As shown in Table 2, the responses of samples from 146 MS patients and 20 CIS patients from whom HLA typing was available showed that patients carrying HLA- DRB1*04, DRB1*07, or DRB1*13 were significantly elevated compared to the “other, other” genotype, and that this was not dependent on the presence of DRB1*15:01, as there were no significant differences between (e.g.,) people with DRB1*04, DRB1*15:01 vs. DRB1*04, other genotype. This evidence concerns the gene HLA-DRB1 and in situ carcinoma.